Clinical Trials Logo

Filter by:
NCT ID: NCT04360148 Active, not recruiting - Overweight Clinical Trials

Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)

EMIKETO
Start date: February 6, 2020
Phase: N/A
Study type: Interventional

The study aims to investigate the impact of 2 nutritional patterns on high-frequency episodic migraine. Subjects enrolled will be randomized in two arms: a) very-low-calorie-ketogenic-diet (VLCKD), b) hypocaloric balanced non ketogenic-diet (HBD).

NCT ID: NCT04353492 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

ARTIOS
Start date: July 14, 2020
Phase: Phase 3
Study type: Interventional

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.

NCT ID: NCT04353349 Active, not recruiting - Lung Cancer Clinical Trials

Impact of Robotic Approach Compared to VATS and Open Approach on Quality of Life in Patients With Lung Cancer

QoL
Start date: April 1, 2016
Phase:
Study type: Observational

The aim of the study is to compare quality of life and early and late post-operative pain after anatomical lung resection (lobectomy or segmentectomy) performed by a robotic approach compared to the videothoracoscopic approach (VATS) and the thoracotomic approach antero-lateral in patients with early stage lung cancer.

NCT ID: NCT04343053 Active, not recruiting - Clinical trials for Severe Acute Respiratory Syndrome Coronavirus 2

Pro-thrombotic Status in Patients With SARS-Cov-2 Infection

ATTAC-Co
Start date: April 8, 2020
Phase: N/A
Study type: Interventional

The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. The observed patterns and changes will be related with inflammatory status, myocardial injury and outcomes

NCT ID: NCT04339946 Active, not recruiting - Clinical trials for Endometriosis, Rectum

Bidimensional Rectal-water Contrast-transvaginal Ultrasonography (2D-RWC-TVS) Versus 3D-RWC-TVS in the Diagnosis of Rectosigmoid Endometriosis

3Dvs2D-RWC-TVS
Start date: January 1, 2018
Phase:
Study type: Observational

An accurate diagnosis of the presence, location and extent of the rectosigmoid endometriosis is of paramount importance for the clinicians in order to inform the patients on the potential surgical or medical treatments. It is well established that transvaginal ultrasonography is the first-line investigation in patients with suspicion of deep infiltrating endometriosis. An improvement in the performance of transvaginal ultrasonography in diagnosing rectosigmoid endometriosis may be obtained by using rectal water contrast during transvaginal ultrasonographic scan.

NCT ID: NCT04338893 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

ROSA Total Knee Post Market Study EMEA

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of surgical workflow efficiency, patient pain and function outcome and adverse events data. This study might include Persona, Nexgen and Vanguard product families using the ROSA Total Knee Robotic system or conventional instrumentation. The primary objective is to evaluate the accuracy of implant alignment for ROSA Total Knee robotic instrumentation compared to conventional instrumentation.

NCT ID: NCT04338399 Active, not recruiting - Clinical trials for Head and Neck Cancer

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

BURAN
Start date: December 12, 2020
Phase: Phase 3
Study type: Interventional

The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.

NCT ID: NCT04338269 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

CONTACT-03
Start date: July 28, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.

NCT ID: NCT04336904 Active, not recruiting - COVID-19 Clinical Trials

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

Start date: March 25, 2020
Phase: Phase 3
Study type: Interventional

This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type.

NCT ID: NCT04328844 Active, not recruiting - NSCLC Clinical Trials

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Start date: February 25, 2020
Phase: Phase 1
Study type: Interventional

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)